Ciclesonide (n=15) | Placebo (n=15) | ||||||
---|---|---|---|---|---|---|---|
Randomisation | Week 8 | p Value | Randomisation | Week 8 | p Value | Between group p | |
Sputum eosinophils (%)* | 0.0 (0.0–2.3) (n=10) | 2.3 (0.5–13.5) (n=11) | 0.263 | 0.0 (0.0–4.3) (n=11) | 4.5 (1.0–9.5) (n=13) | 0.041 | 0.317 |
Sputum neutrophils (%)* | 77.5 (47.6–96.5) (n=10) | 55.8 (38.8–88.5) (n=11) | 0.017 | 79.5 (64.5–94.0) (n=11) | 70.5 (56.8–89.3) (n=13) | 0.799 | 0.155 |
FEV1 (litres)† | 2.6 (0.7) | 2.5 (0.7) | 0.252 | 2.1 (0.7) | 2.0 (0.6) | 0.115 | 0.699 |
ACQ score† | 1.4 (1.1) | 1.8 (1.4) | 0.175 | 1.6 (0.8) | 2.3 (1.3) | 0.051 | 0.318 |
AQLQ score† | 5.8 (1.0) | 5.4 (1.5) | 0.145 | 5.5 (1.2) | 5.0 (1.4) | 0.243 | 0.800 |
FeNO (ppb)‡ | 32.4 (0.4) | 40.6 (0.4) | 0.097 | 30.7 (0.3) | 34.9 (0.3) | 0.292 | 0.598 |
Corrected alveolar NO (ppb)* | 1.7 (0.3–2.5) | 1.4 (0.1–3.0) | 0.925 | 2.0 (0.9–3.1) | 2.4 (1.1–3.6) | 0.730 | 0.528 |
Blood eosinophils (×109/L)* | 0.1 (0.0–0.2) | 0.3 (0.1–0.6) | 0.013 | 0.2 (0.0–0.4) | 0.3 (0.2–0.5) | 0.065 | 0.128 |
*Median (IQR).
†Mean (SD).
‡Geometric mean (log SD).
ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; NO, nitric oxide.